Connor, Clark & Lunn Investment Management (CC&L)’s Atea Pharmaceuticals AVIR Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | – | Sell |
-30,087
| Closed | -$90K | – | 1505 |
|
|
2025
Q1 | $90K | Sell |
30,087
-46,265
| -61% | -$138K | ﹤0.01% | 1356 |
|
|
2024
Q4 | $256K | Buy |
76,352
+32,195
| +73% | +$108K | ﹤0.01% | 1284 |
|
|
2024
Q3 | $148K | Buy |
+44,157
| New | +$148K | ﹤0.01% | 1350 |
|
|
2024
Q2 | – | Sell |
-67,111
| Closed | -$271K | – | 1378 |
|
|
2024
Q1 | $271K | Buy |
67,111
+14,979
| +29% | +$60.5K | ﹤0.01% | 1302 |
|
|
2023
Q4 | $159K | Sell |
52,132
-38,826
| -43% | -$118K | ﹤0.01% | 1285 |
|
|
2023
Q3 | $273K | Buy |
90,958
+2,816
| +3% | +$8.45K | ﹤0.01% | 1167 |
|
|
2023
Q2 | $330K | Buy |
+88,142
| New | +$330K | ﹤0.01% | 1085 |
|